Fox Run Management L.L.C. purchased a new stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 12,700 shares of the biopharmaceutical company’s stock, valued at approximately $637,000. Fox Run Management L.L.C. owned approximately 0.06% of Esperion Therapeutics at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Meditor Group Ltd lifted its position in Esperion Therapeutics by 305.5% in the 3rd quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock valued at $115,022,000 after purchasing an additional 1,728,935 shares during the last quarter. BB Biotech AG lifted its position in Esperion Therapeutics by 7.5% in the 2nd quarter. BB Biotech AG now owns 1,513,542 shares of the biopharmaceutical company’s stock valued at $70,047,000 after purchasing an additional 105,000 shares during the last quarter. State Street Corp lifted its position in Esperion Therapeutics by 264.6% in the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after purchasing an additional 1,093,292 shares during the last quarter. FMR LLC lifted its position in Esperion Therapeutics by 2.3% in the 2nd quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock valued at $61,950,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Discovery Capital Management LLC CT increased its stake in Esperion Therapeutics by 152.9% during the 2nd quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock valued at $44,663,000 after buying an additional 583,529 shares during the period. 89.12% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.truebluetribune.com/2017/11/14/fox-run-management-l-l-c-invests-637000-in-esperion-therapeutics-inc-espr.html.
Several equities analysts have recently issued reports on ESPR shares. Northland Securities reiterated a “buy” rating and issued a $72.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Stifel Nicolaus restated a “buy” rating and set a $70.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Deutsche Bank AG set a $64.00 price target on shares of Esperion Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Jefferies Group LLC upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and decreased their price target for the stock from $85.00 to $55.00 in a report on Tuesday, August 8th. Finally, Cowen and Company started coverage on shares of Esperion Therapeutics in a research note on Thursday, September 7th. They issued an “outperform” rating and a $64.00 target price for the company. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Esperion Therapeutics has a consensus rating of “Buy” and an average target price of $58.92.
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) traded up $0.13 during trading hours on Monday, hitting $48.53. 218,900 shares of the stock traded hands, compared to its average volume of 1,060,332. Esperion Therapeutics, Inc. has a 52 week low of $10.30 and a 52 week high of $57.40.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same period last year, the business posted ($0.77) EPS. sell-side analysts expect that Esperion Therapeutics, Inc. will post -7.21 earnings per share for the current fiscal year.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.